Abstract

The quantification of the enantiomers of racemic substances is of great importance in the development and regulation of pharmaceutical compounds. Active ingredients are often chiral; typically, only one of the stereoisomers has the desired pharmacokinetic and/or pharmacodynamic properties. Therefore, the stereoisomer distribution of chiral drug products must be characterized and evaluated during the drug discovery and development pipeline. Moreover, various chiral drugs present a stereoselective metabolism, highlighting the need for appropriate analytical strategies for the stereoselective analysis of metabolites, for example, in clinical and environmental studies. Due to its ease of use, robustness, and transferability, chiral liquid chromatography (LC) is the most common approach used in pharmaceutical analysis. Compared with LC, supercritical fluid chromatography (SFC) allows higher linear flow velocities while maintaining high chromatographic efficiency, often enabling the reduction of analysis time. In addition, SFC provides enhanced or complementary chiral selectivity and avoids or reduces toxic solvents, such as those used in normal-phase LC. In the first part of this review article the theoretical advantages, technological developments, and common practices in chiral SFC are discussed. This will be followed by a contribution discussing recent applications in pharmaceutical, clinical, forensic, and environmental analysis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.